(Q38268725)

English

Efficacy and safety of biologics in the treatment of moderate to severe psoriasis: a comprehensive meta-analysis of randomized controlled trials.

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25402246%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

0 references

1 reference

Europe PubMed Central

Efficacy and safety of biologics in the treatment of moderate to severe psoriasis: a comprehensive meta-analysis of randomized controlled trials (English)

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25402246%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

Michel Fleith Otuki

8

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25402246%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

author name string

Cassyano Januário Correr

1

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25402246%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

Inajara Rotta

2

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25402246%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

Thaís de Souza Teles

3

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25402246%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

Rangel Ray Godoy

4

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25402246%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

Bruno Salgado Riveros

5

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25402246%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

Mariana Martins Garcia

6

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25402246%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

Patrícia Rodrigues Gonçalves

7

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25402246%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

publication date

1 November 2013

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25402246%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

Cadernos de saúde pública

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25402246%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

29 Suppl 1

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25402246%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

S17-31

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25402246%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

Evidence-based dermatology: number needed to treat and its relation to other risk measures

1 reference

https://api.crossref.org/works/10.1590%2F0102-311X00157013

21 January 2018

Evidence-based recommendations on conventional systemic treatments in psoriasis: systematic review and expert opinion of a panel of dermatologists.

1 reference

https://api.crossref.org/works/10.1590%2F0102-311X00157013

21 January 2018

Efficacy and safety of oral retinoids in different psoriasis subtypes: a systematic literature review.

1 reference

https://api.crossref.org/works/10.1590%2F0102-311X00157013

21 January 2018

Efficacy of systemic treatments for moderate to severe plaque psoriasis: systematic review and meta-analysis

1 reference

https://api.crossref.org/works/10.1590%2F0102-311X00157013

21 January 2018

Safety and efficacy of alefacept, efalizumab, etanercept and infliximab in treating moderate to severe plaque psoriasis: a meta-analysis of randomized controlled trials

1 reference

https://api.crossref.org/works/10.1590%2F0102-311X00157013

21 January 2018

Benefit-risk assessment of tumour necrosis factor antagonists in the treatment of psoriasis

1 reference

https://api.crossref.org/works/10.1590%2F0102-311X00157013

21 January 2018

Biologics in the treatment of psoriasis: clinical and economic overview

1 reference

https://api.crossref.org/works/10.1590%2F0102-311X00157013

21 January 2018

Efficacy of biologics in the treatment of moderate to severe psoriasis: a network meta-analysis of randomized controlled trials

1 reference

https://api.crossref.org/works/10.1590%2F0102-311X00157013

21 January 2018

Comparative effects of biological therapies on the severity of skin symptoms and health-related quality of life in patients with plaque-type psoriasis: a meta-analysis

1 reference

https://api.crossref.org/works/10.1590%2F0102-311X00157013

21 January 2018

Efficacy and tolerability of biologic and nonbiologic systemic treatments for moderate-to-severe psoriasis: meta-analysis of randomized controlled trials

1 reference

https://api.crossref.org/works/10.1590%2F0102-311X00157013

21 January 2018

Assessing the quality of reports of randomized clinical trials: is blinding necessary?

1 reference

https://api.crossref.org/works/10.1590%2F0102-311X00157013

21 January 2018

Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement

1 reference

https://api.crossref.org/works/10.1590%2F0102-311X00157013

21 January 2018

Adalimumab for treatment of moderate to severe chronic plaque psoriasis of the hands and feet: efficacy and safety results from REACH, a randomized, placebo-controlled, double-blind trial

1 reference

https://api.crossref.org/works/10.1590%2F0102-311X00157013

21 January 2018

The effect of adalimumab on reducing depression symptoms in patients with moderate to severe psoriasis: a randomized clinical trial.

1 reference

https://api.crossref.org/works/10.1590%2F0102-311X00157013

21 January 2018

Adalimumab therapy for moderate to severe psoriasis: A randomized, controlled phase III trial.

1 reference

https://api.crossref.org/works/10.1590%2F0102-311X00157013

21 January 2018

Benefit-risk analysis of adalimumab versus methotrexate and placebo in the treatment of moderate to severe psoriasis: comparison of adverse event-free response days in the CHAMPION trial

1 reference

https://api.crossref.org/works/10.1590%2F0102-311X00157013

21 January 2018

Impact of adalimumab treatment on health-related quality of life and other patient-reported outcomes: results from a 16-week randomized controlled trial in patients with moderate to severe plaque psoriasis.

1 reference

https://api.crossref.org/works/10.1590%2F0102-311X00157013

21 January 2018

Impact of adalimumab treatment on patient-reported outcomes: results from a Phase III clinical trial in patients with moderate to severe plaque psoriasis.

1 reference

https://api.crossref.org/works/10.1590%2F0102-311X00157013

21 January 2018

Efficacy and safety results from the randomized controlled comparative study of adalimumab vs. methotrexate vs. placebo in patients with psoriasis (CHAMPION).

1 reference

https://api.crossref.org/works/10.1590%2F0102-311X00157013

21 January 2018

Treatment of chronic plaque psoriasis by selective targeting of memory effector T lymphocytes.

1 reference

https://api.crossref.org/works/10.1590%2F0102-311X00157013

21 January 2018

Improved health-related quality of life following a randomized controlled trial of alefacept treatment in patients with chronic plaque psoriasis

1 reference

https://api.crossref.org/works/10.1590%2F0102-311X00157013

21 January 2018

Treatment of psoriasis with alefacept: correlation of clinical improvement with reductions of memory T-cell counts.

1 reference

https://api.crossref.org/works/10.1590%2F0102-311X00157013

21 January 2018

Clinical response to alefacept: results of a phase 3 study of intravenous administration of alefacept in patients with chronic plaque psoriasis.

1 reference

https://api.crossref.org/works/10.1590%2F0102-311X00157013

21 January 2018

An international, randomized, double-blind, placebo-controlled phase 3 trial of intramuscular alefacept in patients with chronic plaque psoriasis.

1 reference

https://api.crossref.org/works/10.1590%2F0102-311X00157013

21 January 2018

Clinical response to alefacept: results of a phase 3 study of intramuscular administration of alefacept in patients with chronic plaque psoriasis

1 reference

https://api.crossref.org/works/10.1590%2F0102-311X00157013

21 January 2018

Safety and efficacy of ABT-874, a fully human interleukin 12/23 monoclonal antibody, in the treatment of moderate to severe chronic plaque psoriasis: results of a randomized, placebo-controlled, phase 2 trial

1 reference

https://api.crossref.org/works/10.1590%2F0102-311X00157013

21 January 2018

Efficacy and safety of ABT-874, a monoclonal anti-interleukin 12/23 antibody, for the treatment of chronic plaque psoriasis: 36-week observation/retreatment and 60-week open-label extension phases of a randomized phase II trial.

1 reference

https://api.crossref.org/works/10.1590%2F0102-311X00157013

21 January 2018

CLinical experience acquired with the efalizumab (Raptiva) (CLEAR) trial in patients with moderate-to-severe plaque psoriasis: results from a phase III international randomized, placebo-controlled trial.

1 reference

https://api.crossref.org/works/10.1590%2F0102-311X00157013

21 January 2018

Efalizumab for patients with moderate to severe plaque psoriasis: a randomized controlled trial.

1 reference

https://api.crossref.org/works/10.1590%2F0102-311X00157013

21 January 2018

Extended efalizumab therapy improves chronic plaque psoriasis: results from a randomized phase III trial.

1 reference

https://api.crossref.org/works/10.1590%2F0102-311X00157013

21 January 2018

Impact of efalizumab on patient-reported outcomes in high-need psoriasis patients: results of the international, randomized, placebo-controlled Phase III Clinical Experience Acquired with Raptiva (CLEAR) trial [NCT00256139].

1 reference

https://api.crossref.org/works/10.1590%2F0102-311X00157013

21 January 2018

A randomized trial of etanercept as monotherapy for psoriasis.

1 reference

https://api.crossref.org/works/10.1590%2F0102-311X00157013

21 January 2018

Patient-reported outcomes of psoriasis improvement with etanercept therapy: results of a randomized phase III trial.

1 reference

https://api.crossref.org/works/10.1590%2F0102-311X00157013

21 January 2018

Patient-reported outcomes in a randomized trial of etanercept in psoriatic arthritis.

1 reference

https://api.crossref.org/works/10.1590%2F0102-311X00157013

21 January 2018

Once-weekly administration of etanercept 50 mg improves patient-reported outcomes in patients with moderate-to-severe plaque psoriasis.

1 reference

https://api.crossref.org/works/10.1590%2F0102-311X00157013

21 January 2018

Intermittent etanercept therapy in pediatric patients with psoriasis

1 reference

https://api.crossref.org/works/10.1590%2F0102-311X00157013

21 January 2018

Etanercept and clinical outcomes, fatigue, and depression in psoriasis: double-blind placebo-controlled randomised phase III trial.

1 reference

https://api.crossref.org/works/10.1590%2F0102-311X00157013

21 January 2018

Golimumab, a new human tumor necrosis factor alpha antibody, administered every four weeks as a subcutaneous injection in psoriatic arthritis: Twenty-four-week efficacy and safety results of a randomized, placebo-controlled study

1 reference

https://api.crossref.org/works/10.1590%2F0102-311X00157013

21 January 2018

Infliximab improves signs and symptoms of psoriatic arthritis: results of the IMPACT 2 trial

1 reference

https://api.crossref.org/works/10.1590%2F0102-311X00157013

21 January 2018

Efficacy and safety of infliximab monotherapy for plaque-type psoriasis: a randomised trial

1 reference

https://api.crossref.org/works/10.1590%2F0102-311X00157013

21 January 2018

Infliximab improves health-related quality of life in the presence of comorbidities among patients with moderate-to-severe psoriasis.

1 reference

https://api.crossref.org/works/10.1590%2F0102-311X00157013

21 January 2018

Infliximab monotherapy provides rapid and sustained benefit for plaque-type psoriasis

1 reference

https://api.crossref.org/works/10.1590%2F0102-311X00157013

21 January 2018

Infliximab induction therapy for patients with severe plaque-type psoriasis: a randomized, double-blind, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1590%2F0102-311X00157013

21 January 2018

Infliximab improves health related quality of life and physical function in patients with psoriatic arthritis

1 reference

https://api.crossref.org/works/10.1590%2F0102-311X00157013

21 January 2018

The Infliximab Multinational Psoriatic Arthritis Controlled Trial (IMPACT): results of radiographic analyses after 1 year

1 reference

https://api.crossref.org/works/10.1590%2F0102-311X00157013

21 January 2018

Infliximab maintains a high degree of clinical response in patients with active psoriatic arthritis through 1 year of treatment: results from the IMPACT 2 trial

1 reference

https://api.crossref.org/works/10.1590%2F0102-311X00157013

21 January 2018

A randomized comparison of continuous vs. intermittent infliximab maintenance regimens over 1 year in the treatment of moderate-to-severe plaque psoriasis.

1 reference

https://api.crossref.org/works/10.1590%2F0102-311X00157013

21 January 2018

Improvement in quality of life with infliximab induction and maintenance therapy in patients with moderate-to-severe psoriasis: a randomized controlled trial.

1 reference

https://api.crossref.org/works/10.1590%2F0102-311X00157013

21 January 2018

Infliximab monotherapy in Japanese patients with moderate-to-severe plaque psoriasis and psoriatic arthritis. A randomized, double-blind, placebo-controlled multicenter trial

1 reference

https://api.crossref.org/works/10.1590%2F0102-311X00157013

21 January 2018

Ustekinumab, a human interleukin 12/23 monoclonal antibody, for psoriatic arthritis: randomised, double-blind, placebo-controlled, crossover trial.

1 reference

https://api.crossref.org/works/10.1590%2F0102-311X00157013

21 January 2018

Ustekinumab significantly improves symptoms of anxiety, depression, and skin-related quality of life in patients with moderate-to-severe psoriasis: Results from a randomized, double-blind, placebo-controlled phase III trial.

1 reference

https://api.crossref.org/works/10.1590%2F0102-311X00157013

21 January 2018

Ustekinumab improves health-related quality of life in patients with moderate-to-severe psoriasis: results from the PHOENIX 1 trial.

1 reference

https://api.crossref.org/works/10.1590%2F0102-311X00157013

21 January 2018

Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1)

1 reference

https://api.crossref.org/works/10.1590%2F0102-311X00157013

21 January 2018

Identifiers

10.1590/0102-311X00157013

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25402246%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25402246%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q38268725&oldid=1510022039"